CACNA2D1 Is a Novel Biomarker for Tumor Initiating Cells and Has Therapeutic Effect in Non-Small Cel

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:blackcat
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective: Tumor initiating cells (TICs) are a small subpopulation within cancer that is thought to be resistant to conventional therapiesand capable of reinitiating tumors.
其他文献
目的:探讨甲状腺癌累及喉、气管时的外科处理。方法:2000-2010年我院手术治疗晚期分化型甲状腺癌20例,根据分化型甲状腺癌侵犯喉、颈段气管的范围及程度行肿瘤削除术、气管楔形切除缝合术、气管窗状切除胸锁乳突肌肌骨膜瓣修复术、气管袖状切除端端吻合术、气管袖状切除游离前臂皮瓣气管重建术;全喉切或近全切除术。
Objective: Patients (pts) with SCLC respond to initial platinum (PLT) based chemotherapy (CT), but rapidly progress.Combined blockade of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4
Background: Concurrent chemoradiation therapy or induction chemotherapy plus surgery were considered as standard treatment to non-small-cell lung cancer (NSCLC) in stage ⅢA-N2, but the side effect bec
会议
Objective: Several phase Ⅲ studies demonstrated that, compared with traditional chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), as first-linetreatments, contribu
Objective: To assess differences in overall survival among patients with NSCLC using TKIs in first or second line treatment and different TKIs.Method: Collecting patients data in CRF and use SPSS soft
Objective: To investigate the efficacy and safety of the treatment of nitroglycerin combined with docetaxel/carboplatin chemotherapy for the elderly patients with advanced non-small cell lung cancer (
目的:通过吉非替尼(gefitinib)和厄洛替尼(erlotinib)双重耐药非小细胞肺癌(NSCLC)细胞HCC827/ER研究消癌平注射液(XAP)改善gefitinib和erlotinib耐药的作用及机理。方法:通过erlotinib 长期诱导形成耐药细胞株HCC827/ER,MTT检测细胞增殖,Taqman探针实时荧光定量PCR检测Met基因拷贝数,Western blot法检测细胞蛋白
Objective: Proteinkinase CK2 (also known ascasein kinase) is a highlyconserved seine/threonine protein kinase, which is ubiquitously expressed inmammalian cells.CK2 has been implicated in multiple phy
Objective: Stem-like cells in solid tumors are purported to contribute to cancer development and poor treatment outcome.The abilities to self-renew, differentiate, and resist anticancer therapies are
Objective: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined.